Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

PURPOSE: In a phase II trial in patients with metastatic triple-negative breast cancer (mTNBC; NCT02978716), administering trilaciclib prior to gemcitabine plus carboplatin (GCb) enhanced T-cell activation and improved overall survival versus GCb alone. The survival benefit was more pronounced in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Antoinette R., O’Shaughnessy, Joyce, Cao, Subing, Ahn, Sarah, Yi, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361859/
https://www.ncbi.nlm.nih.gov/pubmed/37418031
http://dx.doi.org/10.1007/s10549-023-07009-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361859/
https://www.ncbi.nlm.nih.gov/pubmed/37418031
http://dx.doi.org/10.1007/s10549-023-07009-8

Ejemplares similares